

This presentation was prepared by Ambev S.A. ("Ambev" or "Company") for the exclusive use in the earnings conference call of the third quarter of 2022 (3Q22). This presentation should not be considered as a complete document and should be analyzed together with the Company's quarterly information form (ITR) for the third quarter and the respective press release, both available on the U.S. Securities and Exchange Commission – SEC and the CVM website. This presentation was prepared for informational purposes only and should not be considered as a solicitation or offer to buy or sell any securities of the Company, or as advice or recommendation of any nature. This presentation is not intended to be comprehensive, or to contain all the information that Ambev's shareholders might need. No decisions on investment, disposal or any other financial decisions or actions shall be made solely on the basis of the information contained herein.

This presentation segregates the impact of organic changes from those arising from changes in scope or currency translation. Scope changes represent the impact of acquisitions and divestitures, the start up or termination of activities or the transfer of activities between segments, curtailment gains and losses and year over year changes in accounting estimates and other assumptions that management does not consider as part of the underlying performance of the business. Organic growth and normalized numbers are presented applying constant year-over-year exchange rates to exclude the impact of the movement of foreign exchange rates.

Unless stated, percentage changes in this press release are both organic and normalized in nature. Whenever used in this document, the term "normalized" refers to performance measures EBITDA and Operating Profit before exceptional items and share of results of joint ventures and to performance measures Profit and EPS before exceptional items adjustments. Exceptional items are either income or expenses which do not occur regularly as part of the normal activities of the Company. They are presented separately because they are important for the understanding of the underlying sustainable performance of the Company due to their size or nature. Normalized measures are additional measures used by management and should not replace the measures determined in accordance with IFRS as indicators of the Company's performance. Comparisons, unless otherwise stated, refer to the third quarter of 2021 (3Q21). Values in this release may not add up due to rounding.



Consistent implementation of strategy



+1.3% VS LY Consolidated volumes



+17.4% VS LY Net revenue/HL



Premium brands mix





+10.6% EBITDA vs LY

Consistent implementation of strategy



+1.3% VS LY Consolidated volumes



+17.4% VS LY Net revenue/HL







Macro volatility





Supply chain constraints

CAC Canada LAS



















-18.7% Volume vs LY

+3.4%

Volume vs LY

+4.5%

Volume vs LY














... with a very well positioned portfolio...















... and BEES allowing us to serve more customers









+HSD
Premium volume vs LY

+17.0%

Net revenue/HL vs LY

+17.7%

EBITDA vs LY

+20bps

EBITDA margin vs LY







BRAHMA





Brands for each

Together Better World



FIFA WORLD CUP Qat_ar2022 the future













Brazil driving Ambev's results

3Q22 Organic Net Revenue growth (BRL mm)



3Q22 Organic Normalized EBITDA growth (BRL mm)



Below EBITDA and CF

R\$ 6.1 b Cash Flow from Operating Activities

R\$ -48m Working Capital

+4.1% YTD Normalized Profit

ESG Day (Nov 3rd)

Climate resilience along value chain

Cultural transformation

Roundtable with members of the board

3Q22 was a good start to 2H22

Ambitions for the year:

- 1. Brazil back to growth
- 2. Consolidated organic EBITDA above growth of 2021
- 3. H2 better than H1 in organic Net Revenue and EBITDA, setting us up for a good 2023

3Q22 was a good start to 2H22

Ambitions for the year:

- 1. Brazil back to growth
- 2. Consolidated organic EBITDA above growth of 2021
- 3. H2 better than H1 in organic Net Revenue and EBITDA, setting us up for a good 2023

Focus for 2023

- 1. Protect liquidity
- 2. Improve profitability ROIC & margins
- 3. Strong cash flow



